Biotech Values

[DewDiligence]

How EGRX used the “Depomed threat” to obtain orphan-drug exclusivity (ODE) for Ryanodex:

http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/09/how-effective-is-a-depomed-threat-at-resolving-an-orphan-drug-clinical-superiority-dispute.html

The same reasoning ought to hold when the FDA rules on ODE status for EGRX’s rapid-infusion Treanda. Note that TEVA waived ODE for branded Trenda as part of its Feb 2015 settlement with EGRX (#msg-110943484).